Literature DB >> 28550985

Opioid Hypersensitivity: Predictors of Allergy and Role of Drug Provocation Testing.

Philip H Li1, Kok Loong Ue2, Annette Wagner3, Ryszard Rutkowski4, Krzysztof Rutkowski5.   

Abstract

BACKGROUND: True IgE-mediated hypersensitivity to opioids is rare and many reactions are due to direct mast cell degranulation. Opioid drug provocation testing (DPT) is the gold standard for diagnosis but is underutilized.
OBJECTIVE: The objective of this study was to evaluate the clinical characteristics and predictors of opioid hypersensitivity, as well as outcomes of opioid DPT.
METHODS: Patients referred for opioid DPT over the past 9 years were studied. Patient characteristics, indications for opioid use, symptoms of index reaction, and outcomes of DPT were analyzed. Association analysis was performed to study variables associated with a diagnosis of opioid hypersensitivity.
RESULTS: Of the total of 98 patients referred with suspected opioid hypersensitivity, 15 (15%) were diagnosed with opioid allergy. Angioedema (odds ratio [OR]: 5.66; 95% confidence interval [CI]: 1.49-21.47; P = .011) and hypotension (OR: 5.00; 95% CI: 1.15-21.70; P = .032) were significantly more frequent in opioid allergic patients than those with a negative DPT. Patients who received opioids during anesthesia were significantly more likely to be opioid allergic (OR: 6.74; 95% CI: 2.05-22.13; P = .001). In contrast, a negative association was identified with patients who received opioids for analgesia (OR: 0.27; 95% CI: 0.08-0.86; P = .008).
CONCLUSIONS: Only 15% of our cohort were diagnosed with opioid allergy, emphasizing the importance of DPT in preventing erroneous overdiagnosis. Patients with a history of angioedema or hypotension as their index reaction were significantly more likely to be opioid allergic. DPT are safe when performed by experienced clinicians after risk stratification and using individualized protocols.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; Hypersensitivity; Opioid; Predictors; Provocation; Skin testing

Mesh:

Substances:

Year:  2017        PMID: 28550985     DOI: 10.1016/j.jaip.2017.03.035

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Allergic Contact Dermatitis to Fentanyl TTS with Good Tolerance to Systemic Fentanyl.

Authors:  Patricia Rojas-Pérez-Ezquerra; Sarah Micozzi; Ines Torrado-Español; Ana Rodríguez-Fernández; Vicente Albéndiz-Gutiérrez; Blanca Noguerado-Mellado
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

Review 2.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

3.  Epirubicin-induced Kounis syndrome.

Authors:  Hui-Zhu Liang; Hong Zhao; Jian Gao; Cheng-Fu Cao; Wei-Min Wang
Journal:  BMC Cardiovasc Disord       Date:  2021-03-12       Impact factor: 2.298

4.  Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study.

Authors:  Guilherme S Lopes; Suzette Bielinski; Ann M Moyer; Debra J Jacobson; Liwei Wang; Ruoxiang Jiang; Nicholas B Larson; Virginia M Miller; Ye Zhu; Dana C Cavanaugh; Jennifer St Sauver
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 3.006

Review 5.  Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2).

Authors:  Mukesh Kumar; Karthi Duraisamy; Billy-Kwok-Chong Chow
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

6.  Kounis syndrome: a clinical entity penetrating from pediatrics to geriatrics.

Authors:  Mattia Giovannini; Ioanna Koniari; Francesca Mori; Silvia Ricci; Luciano De Simone; Silvia Favilli; Sandra Trapani; Giuseppe Indolfi; Nicholas George Kounis; Elio Novembre
Journal:  J Geriatr Cardiol       Date:  2020-05       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.